Trial Profile
Multi Center, Randomized, Double-blind, Active Controlled, Parallel Design, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-351 in Primary Open Angle Glaucoma or Ocular Hypertension Patients
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Dorzolamide+Latanoprost (Primary) ; D 930; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Chong Kun Dang
- 11 Dec 2018 New trial record